DE69525148D1 - Pharmazeutische formulierung - Google Patents

Pharmazeutische formulierung

Info

Publication number
DE69525148D1
DE69525148D1 DE69525148T DE69525148T DE69525148D1 DE 69525148 D1 DE69525148 D1 DE 69525148D1 DE 69525148 T DE69525148 T DE 69525148T DE 69525148 T DE69525148 T DE 69525148T DE 69525148 D1 DE69525148 D1 DE 69525148D1
Authority
DE
Germany
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69525148T
Other languages
English (en)
Other versions
DE69525148T2 (de
Inventor
Francis Walter Grimmett
Nigel Philip Mccreath Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE69525148D1 publication Critical patent/DE69525148D1/de
Application granted granted Critical
Publication of DE69525148T2 publication Critical patent/DE69525148T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
DE69525148T 1994-04-14 1995-04-07 Pharmazeutische formulierung Expired - Fee Related DE69525148T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9407386A GB9407386D0 (en) 1994-04-14 1994-04-14 Pharmaceutical formulation
PCT/EP1995/001269 WO1995028148A1 (en) 1994-04-14 1995-04-07 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
DE69525148D1 true DE69525148D1 (de) 2002-03-14
DE69525148T2 DE69525148T2 (de) 2002-09-05

Family

ID=10753514

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69525148T Expired - Fee Related DE69525148T2 (de) 1994-04-14 1995-04-07 Pharmazeutische formulierung

Country Status (6)

Country Link
US (3) US6136345A (de)
EP (1) EP0752850B1 (de)
JP (1) JPH09511994A (de)
DE (1) DE69525148T2 (de)
GB (1) GB9407386D0 (de)
WO (1) WO1995028148A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AUPS270602A0 (en) 2002-05-31 2002-06-20 Baron, Peter Drink flavouring straw
US20030087005A1 (en) * 1996-10-10 2003-05-08 Peter Baron Drink flavouring straw
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
CN1194687C (zh) * 1997-02-14 2005-03-30 史密斯克莱恩比彻姆药物实验室 含有阿莫西林和克拉维酸盐的药物制剂
JP3950175B2 (ja) * 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
KR100502478B1 (ko) * 1997-06-13 2005-12-02 동아제약주식회사 클라불란산과베타락탐계항생물질을포함하는세균감염증치료제용약학적조성물
AU767177B2 (en) * 1999-04-13 2003-11-06 Beecham Pharmaceuticals (Pte) Limited Novel method of treatment
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
AU3986901A (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
EP1265599A4 (de) * 2000-02-24 2006-01-18 Advancis Pharmaceutical Corp Antibiotische zubereitung mit hemmstoff
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (de) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Amoxicillinhaltige arzneizusammensetzungen
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20030143272A1 (en) * 2001-03-14 2003-07-31 Waterman Kenneth C. Pharmaceutical tablet and process for making thereof
ATE330586T1 (de) * 2001-03-14 2006-07-15 Pfizer Prod Inc Pharmazeutische tablette und eine verfahren zu deren herstellung
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
AU2003269741A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
WO2005007135A1 (en) * 2002-08-15 2005-01-27 Euro-Celtique S.A. Pharmaceutical compositions
US6803046B2 (en) 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US8617617B2 (en) * 2002-12-10 2013-12-31 Everett Laboratories, Inc. Methods and kits for co-administration of nutritional supplements
US6814983B2 (en) * 2002-12-10 2004-11-09 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20060121106A1 (en) * 2003-02-21 2006-06-08 Janez Kerc Therapeutic system comprising amoxicillin and clavulanic acid
BRPI0408599A (pt) * 2003-05-02 2006-03-21 Warner Lambert Co produtos de confeitaria para distribuição de agentes farmaceuticamente ativos para a garganta
WO2005009368A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1653925A1 (de) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
CA2540059C (en) * 2003-09-26 2013-08-06 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
EP1673073A4 (de) * 2003-09-29 2012-03-21 Cj Cheiljedang Corp Formulierungen mit verzögerter freisetzung
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
KR100638315B1 (ko) * 2004-07-23 2006-10-25 주식회사 대웅제약 다중 필름 코팅된 코어층을 갖는 클라불라네이트 및아목시실린-함유 유핵정
DE102004035938A1 (de) * 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil
US8101587B2 (en) * 2004-08-12 2012-01-24 Everett Laboratories, Inc. Kits for nutrition supplementation
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
EP1681050A1 (de) * 2005-01-13 2006-07-19 Strides Arcolab Limited Dispergierbare pharmazeutische Zusammensetzung mit verzögerter Freisetzung
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2006322314A1 (en) * 2005-11-18 2007-06-14 Synthon B.V. Zolpidem tablets
WO2007059916A2 (en) * 2005-11-23 2007-05-31 Sandoz Ag Pharmaceutical composition
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
AR060029A1 (es) * 2006-03-02 2008-05-21 Unistraw Patent Holdings Ltd Pajilla para beber adaptada para acondicionar progresivamente un ingrediente activo y metodo de fabricar dicha pajilla
EA020867B1 (ru) * 2006-03-06 2015-02-27 Поузен Инк. Лекарственные формы для введения комбинаций лекарственных средств
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2008029351A2 (en) * 2006-09-04 2008-03-13 Ranbaxy Laboratories Limited A modified release formulation comprising amoxicillin and clavulanate
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
PT2178513E (pt) * 2007-06-22 2011-05-31 Bristol Myers Squibb Co Composi??es em comprimido que cont?m atazanavir
JP2010530889A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
DK2170292T3 (da) * 2007-06-22 2014-04-07 Bristol Myers Squibb Holdings Ireland Atazanavirholdige sammensætninger i tabletform
WO2009002826A2 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
AU2010249103B2 (en) 2009-05-12 2015-02-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
US8709477B2 (en) * 2009-08-13 2014-04-29 Kremers Urban Pharmaceuticals, Inc` Pharmaceutical dosage form
US9173860B2 (en) * 2009-11-04 2015-11-03 Susan Park Perrine S isomers of α-methyl hydrocinnamic acid for the treatment of blood disorders
CA2782285A1 (en) 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
EP2509587A2 (de) * 2009-12-07 2012-10-17 McNeil-PPC, Inc. Teilweise tauchbeschichtung von darreichungsformen für modifizierte freisetzung
CA2784919A1 (en) 2010-01-26 2011-07-26 Banyan Biomarkers, Inc. Compositions and methods relating to argininosuccinate synthetase
US8889672B2 (en) 2011-04-29 2014-11-18 The Regents Of The University Of Michigan Compounds, formulations, and methods of protein kinase C inhibition
SI2701708T1 (sl) 2011-04-29 2020-07-31 The Penn State Research Foundation Induciranje malomolekulskega gena TRAIL z normalnimi in tumorskimi celicami kot terapija proti raku
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
WO2013057569A2 (en) * 2011-10-19 2013-04-25 Micro Labs Limited Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
US9682093B2 (en) 2012-03-30 2017-06-20 Charles R. Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
AU2013361164A1 (en) 2012-12-20 2015-07-02 The Penn State Research Foundation Methods and compositions relating to treatment of cancer
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2015089416A1 (en) 2013-12-12 2015-06-18 Cornell University Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
DE3814532A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Dhp-retard-zubereitung
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
FI93924C (fi) 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
IT1289160B1 (it) 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
AU767177B2 (en) 1999-04-13 2003-11-06 Beecham Pharmaceuticals (Pte) Limited Novel method of treatment

Also Published As

Publication number Publication date
US20020086056A1 (en) 2002-07-04
JPH09511994A (ja) 1997-12-02
WO1995028148A1 (en) 1995-10-26
US6136345A (en) 2000-10-24
EP0752850A1 (de) 1997-01-15
GB9407386D0 (en) 1994-06-08
US6358528B1 (en) 2002-03-19
EP0752850B1 (de) 2002-01-23
DE69525148T2 (de) 2002-09-05
US6838094B2 (en) 2005-01-04

Similar Documents

Publication Publication Date Title
DE69525148D1 (de) Pharmazeutische formulierung
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
ID24654A (id) Formulasi farmasi omeprazola
DE69622735T2 (de) Lyophilisierte stabile pharmazeutische formulierung
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
DE69621885D1 (de) Neue galenische orale pharmazeutische formulierung
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
ATE203400T1 (de) Pharmazeutische formulierungen
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
NO981008D0 (no) Farmasöytisk formulering
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
DE4294862T1 (de) Pharmazeutische Komposition
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
DE69614407T2 (de) Pharmazeutische zusammensetzungen
ID16781A (id) Formulasi-formulasi farmasi
ATE295150T1 (de) Pharmazeutische zusammensetzungen
ATE208364T1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
ITMI941169A0 (it) Formulazioni farmaceutiche
FI973230A (fi) Uusi farmaseuttinen formulaatio
FI951155A0 (fi) Farmaseuttinen valmiste

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee